In patients with ovarian cancers that are wild-type for BRCA1/2, BRCA1 promoter methylation predicted better outcome to platinum-taxane based therapy [130] as well as PARP inhibition, as compared to patients without such methylation, thus mirroring findings in patients harbouring germline mutations [131–133]. Here, BRCA1 is linked to ovarian cancer.